Breaking News Instant updates and real-time market news.

ABEO

Abeona Therapeutics

$5.00

0.1 (2.04%)

, NAVB

Navidea

$0.53

0.0039 (0.74%)

04:55
06/22/17
06/22
04:55
06/22/17
04:55

Biotechnology Innovation Organization to hold a convention

BIO International Convention is being held in San Diego, CA on June 19-22.

ABEO

Abeona Therapeutics

$5.00

0.1 (2.04%)

NAVB

Navidea

$0.53

0.0039 (0.74%)

XON

Intrexon

$23.95

0.65 (2.79%)

FBIO

Fortress Biotech

$4.79

-0.05 (-1.03%)

ADXS

Advaxis

$6.09

0.15 (2.53%)

ACRX

AcelRx

VICL

Vical

$2.47

0.05 (2.07%)

TNXP

Tonix Pharmaceuticals

$4.26

0.08 (1.91%)

  • 29

    Jun

  • 12

    Oct

ABEO Abeona Therapeutics
$5.00

0.1 (2.04%)

03/06/17
03/06/17
NO CHANGE

FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
01/06/17
JEFF
01/06/17
INITIATION
Target $11
JEFF
Buy
Abeona Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Gena Wang started Abeona Therapeutics with a Buy rating and $11 price target. The analyst sees a favorable risk/reward ahead of data readouts in the first half of 2017.
09/29/16
MAXM
09/29/16
NO CHANGE
Target $14
MAXM
Buy
Abeona Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised Abeona's price target to $14 from $8 saying he expects multiple data points across several gene therapy programs to potentially push shares higher. The analyst said clinical development is underway in Abeona's Sanfilippo with positive data in two patients so far, and data from more patients are expected this fall. The company is also advancing a second Sanfilippo gene therapy, ABO-101, into the clinic later this year. Also, Abeona has brought on board a more advanced gene therapy from Stanford University, EB-101, to treat a rare skin disease which demonstrated positive data in five patients and has advanced to phase II, McCarthy wrote.
12/12/16
CANT
12/12/16
NO CHANGE
Target $21
CANT
Abeona short report 'factually incorrect and misleading,' says Cantor
Cantor Fitzgerald analyst Elemer Piros said the short report published on Seeking Alpha regarding Abeona Therapeutics is "factually incorrect and misleading." Abeona infuses its drug to the bloodstream, unlike Lysogene, whose failed clinical trial was conducted with a gene therapy that was directly injected into a handful of brain regions, Piros points out. Abeona also employs an AAV9 vector, which "delivers and promotes expression" in both neurons and glial cells, according to Piros, who reiterates his Buy rating and $21 price target on Abeona shares.
NAVB Navidea
$0.53

0.0039 (0.74%)

XON Intrexon
$23.95

0.65 (2.79%)

02/03/17
JMPS
02/03/17
NO CHANGE
Target $42
JMPS
Outperform
Dominion allows isobutanol option with Intrexon to expire, says JMP Securities
JMP Securities analyst Jason Butler said that Intrexon (XON) management confirmed in conversations with him yesterday after the markets closed that Dominion (D) allowed its option with Intrexon Energy Partners for isobutanol production facilities in North America to expire without opting in. While "somewhat disappointing," Butler said he remains confident that Intrexon and the IEP joint venture, which was formed with undisclosed investors that do not include Dominion, are making progress and Dominion's decision should not impact IEP's ability to continue advancing its efforts toward commercial production. He reiterates an Outperform rating and $42 price target on Intrexon shares.
01/25/17
RODM
01/25/17
DOWNGRADE
Target $7
RODM
Neutral
GenVec downgraded to Neutral from Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju downgraded GenVec (GNVC) to Neutral citing the takeover by Intrexon (XON). The analyst views the offer as "decent" and lowered his price target for GenVac shares to $7 from $15.
12/29/16
12/29/16
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst upgrades, downgrades, and initiations with this list compiled by The Fly: 1. Basic Energy (BAS) upgraded to Accumulate from Hold at Johnson Rice. 2. GameStop (GME) upgraded to Buy from Hold at Standpoint Research. 3. Anthera (ANTH) downgraded to Neutral from Buy at Citi and to Hold from Buy at Jefferies. 4. Senior Housing (SNH) initiated with an Overweight at Cantor. 5. Intrexon (XON) initiated with an Outperform at Northland with analyst Robert Breza saying valuation is compelling and its DNA analysis and engineering platform addresses a large market opportunity. The analyst views Deere's FY17 guidance as achievable. He kept an Outperform rating on the shares with a $117 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/16
NORL
12/29/16
INITIATION
Target $40
NORL
Outperform
Intrexon initiated with an Outperform at Northland
Northland analyst Robert Breza initiated Intrexon with an Outperform and a $40 price target saying valuation is compelling and its DNA analysis and engineering platform addresses a large market opportunity.
FBIO Fortress Biotech
$4.79

-0.05 (-1.03%)

03/22/17
JMPS
03/22/17
INITIATION
Target $11
JMPS
Outperform
Fortress Biotech initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King initiated Fortress Biotech with an Outperform and an $11 price target.
10/03/16
ROTH
10/03/16
INITIATION
Target $9
ROTH
Buy
Fortress Biotech initiated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis started Fortress Biotech with a Buy rating and $9 price target.
03/22/17
JMPS
03/22/17
INITIATION
JMPS
Outperform
Fortress Biotech initiated at JMP Securities
As noted earlier, JMP Securities started coverage of Fortress Biotech with an Outperform rating. Analyst Michael King is upbeat on the track record of the company's management and its ability to acquire drugs that will generate "substantial and diverse revenue streams." Target $11.
ADXS Advaxis
$6.09

0.15 (2.53%)

11/30/16
11/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Shutterfly (SFLY) initiated with a Buy at Aegis. 2. WageWorks (WAGE) initiated with a Buy at Chardan. 3. BorgWarner (BWA) initiated with a Buy at Jefferies. 4. Advaxis (ADXS) initiated with a Buy at Cantor. 5. Xtant (XTNT) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
CANT
11/30/16
INITIATION
Target $19
CANT
Buy
Advaxis initiated with a Buy at Cantor
Cantor analyst Mara Goldstein initiated Advaxis with a Buy and a $19 price target.
ACRX AcelRx

10/04/16
JEFF
10/04/16
NO CHANGE
Target $7
JEFF
Buy
Jefferies says physician survey bodes well for AcelRx
Jefferies analyst Hugo Ong says his firm's first Emergency Department physician survey on trends for acute pain management suggests a positive outlook for AcelRx's ARX-04. Physicians expect to use the drug, which could be available by the end of 2017, in 19% of their patients with moderate pain and 27% with severe pain in 2018, Ong tells investors in a research note. He believes the survey bodes well for ARX-04 and reiterates a Buy rating on AcelRx with a $7 price target.
09/15/16
ROTH
09/15/16
NO CHANGE
Target $15
ROTH
Buy
AcelRx price target raised to $15 from $11 at Roth Capital
VICL Vical
$2.47

0.05 (2.07%)

07/19/16
HCWC
07/19/16
INITIATION
Target $12
HCWC
Buy
Vical assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical with a Buy rating and $12 price target.
06/12/17
RODM
06/12/17
INITIATION
Target $9
RODM
Buy
Vical initiated assumed a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju assumed coverage of Vical with a Buy rating and $9 price target. Vical continues to trade at a market cap below the most recently reported cash position despite its "diversified pipeline of clinical-stage assets," the analyst writes.
TNXP Tonix Pharmaceuticals
$4.26

0.08 (1.91%)

09/07/16
CANT
09/07/16
DOWNGRADE
CANT
Hold
Tonix Pharmaceuticals downgraded to Hold from Buy at Cantor
Cantor analyst Chiara Russo downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint. Russo notes that the company now plans to pursue PTSD as the lead indication, but the analyst continue to "remain cautious" on that indication. Target to $1 from $5.
09/07/16
ROTH
09/07/16
DOWNGRADE
Target $1.25
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy as he re-evaluates its PTSD program given that it is now the primary lever for the shares after the company reported that Tonmya phase 3 data to treat fibromyalgia did not achieve its primary endpoint. The analyst also lowered his price target on the shares to $1.25 from $7.5.
09/07/16
OPCO
09/07/16
DOWNGRADE
OPCO
Perform
Tonix Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint.

TODAY'S FREE FLY STORIES

XRAY

Dentsply Sirona

$65.65

-0.14 (-0.21%)

07:32
01/17/18
01/17
07:32
01/17/18
07:32
Hot Stocks
Dentsply Sirona appoints Donald Casey Jr. as CEO »

Dentsply Sirona announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Conference/Events
Federal Reserve Bank of Dallas President participates in a discussion »

Dallas Federal Reserve…

LCII

LCI Industries

$123.65

-2.75 (-2.18%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Hot Stocks
LCI Industries to acquire Taylor Made Group, terms not disclosed »

LCI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNHI

CNH Industrial

$14.72

-0.21 (-1.41%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Initiation
CNH Industrial initiated  »

CNH Industrial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

PAVM

PAVmed

$2.84

-0.12 (-4.05%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Hot Stocks
PAVmed announces terms of previously announced rights offering »

PAVmed Iannounced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$101.06

-0.23 (-0.23%)

, SPLK

Splunk

$87.13

-2.51 (-2.80%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Conference/Events
House Homeland Security Committee to hold a hearing »

The Cybersecurity and…

DXC

DXC Technology

$101.06

-0.23 (-0.23%)

SPLK

Splunk

$87.13

-2.51 (-2.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

GME

GameStop

$17.16

-0.6 (-3.38%)

, AREX

Approach Resources

$3.62

-0.29 (-7.42%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GME

GameStop

$17.16

-0.6 (-3.38%)

AREX

Approach Resources

$3.62

-0.29 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Aeterna Zentaris »

Aeterna Zentaris trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKS

Dick's Sporting

$32.33

-1 (-3.00%)

07:29
01/17/18
01/17
07:29
01/17/18
07:29
Upgrade
Dick's Sporting rating change  »

Dick's Sporting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$132.14

-0.39 (-0.29%)

07:29
01/17/18
01/17
07:29
01/17/18
07:29
Recommendations
VMware analyst commentary  »

VMware price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 19

    Jan

07:28
01/17/18
01/17
07:28
01/17/18
07:28
Conference/Events
Fitch Ratings to hold a teleconference »

Fitch Analysts provide…

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Conference/Events
The Executives' Club of Chicago holds a luncheon meeting »

The Executives' Club…

TI

Telecom Italia

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Downgrade
Telecom Italia rating change  »

Telecom Italia downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DF

Dean Foods

$11.28

0.01 (0.09%)

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Upgrade
Telefonica rating change  »

Telefonica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$146.86

1.1 (0.75%)

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Periodicals
J&J attracts Chinese interest for diabetes business, Reuters reports »

Chinese suitors have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

VOD

Vodafone

$32.33

0.4 (1.25%)

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Upgrade
Vodafone rating change  »

Vodafone upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:26
01/17/18
01/17
07:26
01/17/18
07:26
Conference/Events
CFA Society of Atlanta to hold a luncheon meeting »

Luncheon Meeting with…

07:25
01/17/18
01/17
07:25
01/17/18
07:25
Conference/Events
Governor of the Bank of Canada to hold a press conference »

Governor of the Bank of…

07:25
01/17/18
01/17
07:25
01/17/18
07:25
Conference/Events
UBS automotive analyst holds an analyst/industry conference call »

Automotive Analyst Hummel…

TEAM

Atlassian

$52.82

0.25 (0.48%)

07:24
01/17/18
01/17
07:24
01/17/18
07:24
Recommendations
Atlassian analyst commentary  »

Atlassian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 26

    Feb

QCOM

Qualcomm

$68.25

2.87 (4.39%)

, AVGO

Broadcom

$263.25

-1.04 (-0.39%)

07:24
01/17/18
01/17
07:24
01/17/18
07:24
Recommendations
Qualcomm, Broadcom analyst commentary  »

Qualcomm target raised to…

QCOM

Qualcomm

$68.25

2.87 (4.39%)

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

AVXS

AveXis

$105.01

-12.49 (-10.63%)

07:23
01/17/18
01/17
07:23
01/17/18
07:23
Recommendations
AveXis analyst commentary  »

Nomura continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FB

Facebook

$178.39

-0.98 (-0.55%)

, TWTR

Twitter

$24.66

-0.75 (-2.95%)

07:22
01/17/18
01/17
07:22
01/17/18
07:22
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Committee holds a…

FB

Facebook

$178.39

-0.98 (-0.55%)

TWTR

Twitter

$24.66

-0.75 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.